Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300
Debt
Debt-to-Equity Ratio0.84
Current Ratio3.98
Quick Ratio3.59
Price-To-Earnings
Trailing P/E Ratio-10.98
Forward P/E Ratio-9.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.95 million
Price / Sales4.77
Cash FlowN/A
Price / CashN/A
Book Value$1.09 per share
Price / Book9.17
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-31,000,000.00
Net Margins-42.30%
Return on Equity-80.99%
Return on Assets-39.72%
Miscellaneous
Employees246
Outstanding Shares34,350,000
Market Cap$349.30
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) posted its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The biotechnology company had revenue of $20.04 million for the quarter, compared to the consensus estimate of $18.28 million. Veracyte had a negative net margin of 42.30% and a negative return on equity of 80.99%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What price target have analysts set for VCYT?
4 analysts have issued 1-year target prices for Veracyte's shares. Their predictions range from $5.40 to $13.00. On average, they expect Veracyte's stock price to reach $9.1333 in the next twelve months. This suggests that the stock has a possible downside of 8.6%. View Analyst Ratings for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Natera (NTRA), RadNet (RDNT), InVitae (NVTA), CareDx (CDNA), Enzo Biochem (ENZ), Celcuity (CELC), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and CBA Florida (CBAI).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 60)
- Mr. Christopher M. Hall, Pres & COO (Age 49)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 48)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 59)
- Mr. Ashish Kheterpal, Chief Information Officer
Has Veracyte been receiving favorable news coverage?
News headlines about VCYT stock have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Veracyte earned a media sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.38 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Veracyte's major shareholders?
Veracyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.89%) and Bank of Montreal Can (0.06%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which institutional investors are buying Veracyte stock?
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $9.99.
How big of a company is Veracyte?
Veracyte has a market capitalization of $349.30 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
